Shanghai Mabgeek Biotech Co., Ltd is a clinical-stage innovative antibody drug development biotech focusing on the Immuno-Inflammation field. The most advanced project anti-IL-4Rα antibody MG-K10 is entering phase III and just gained clinical data as Best-in-Class in moderate-to-severe atopic dermatitis (AD) phase II clinical trial. MG-K10 has been confirmed to have potential in treating all Th2 related disease, including AD, asthma, rhinosinusitis, prurigo nodularis, esophagitis and so on. The annual sale of the only launched anti-IL-4R, Dupilumab, has reached more than 8 billion Eur in 2022. The phase II clinical results of MG-K10 confirmed it to be best-in-class. While Dupilumab needs to be dosed Q2W, MG-K10 is highly effective and well tolerated dosed Q4W. No matter in Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA) and body surface area (BSA) improvement, or in patient reported numeric rating scales (NRS), MG-K10 Q4W significantly improved all the parameters after 16 weeks of treatment. And this will be the first time the detailed data presented to the public. In the pipeline we also have anti-TSLP (on phase I), anti-IL-33, and anti-MASP-2 mAb, all developed by our unique TEADA hybridoma platform and with half life extended, all with best-in-class potential. The main focus of the company has been three areas: The respiratory, with the anti-IL-4R, anti-TSLP and anti-IL-33 may be supplemental in fighting the asthma and COPD in Th2 and non-Th2, former smoker and current smoker population. The dermatology, targeting the AD, Urticaria, prurigo nodularis and bullous pemphigoid; also the Nephrology, targeting the IgA Nephropathy and diabetic kidney disease. With our speciality, all of the mAb drug developed has been high concentration, from 100 mg/ml to 150 mg/ml, high affinity, high biological activity, and high drug developability. We have over 10 issued and pending patents worldwide to protect our platform and drug candidates.